RecruitingLymphoma, Non-HodgkinB-cell LymphomaLymphoma, Large B-Cell, Diffuse

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Eligible age

18+ yrs

Accepts

All genders

Locations

18 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.

Sponsor: Eli Lilly and Company

You may qualify if…

✓ Must have a diagnosis of either follicular lymphoma or diffuse large B-cell lymphoma.
✓ Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
✓ Estimated life expectancy of greater than or equal to (≥)12 weeks as judged by the Investigator.
✓ Participants with select tumor types must have measurable or assessable disease as defined below:
✓ Participants with lymphoma must have at least 1 bi-dimensionally measurable lesion or in the absence of measurable lymphadenopathy, documentation of bone marrow involvement.
✓ Participants with Waldenstrom macroglobulinemia (WM) must have measurable disease, defined as the presence of serum IgM with a minimum IgM level of greater than (\>)2 times (×) upper limit of normal (ULN) based on local laboratory testing.
✓ Must be able to comply with inpatient/outpatient treatment, laboratory monitoring, and required clinic visits for the duration of trial participation.
✓ Must have adequate organ function.

You may not qualify if…

✕ All Participants
✕ Known or suspected peripheral blood involvement by malignant cells with an absolute lymphocyte count of greater than or equal to (≥) 5000 cells per microliter (μL).
✕ Known or suspected central nervous system (CNS) involvement by systemic lymphoma.
✕ Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
✕ Any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade 2 at the time of starting trial treatment except for alopecia.
✕ Autologous stem cell transplantation within 100 days of this study for post autologous transplant individuals.
✕ Residual symptoms of neurotoxicity or cytopenias from prior chimeric antigen receptor T-cell therapy (CAR-T) or bispecifics. Exception: Cytopenia related to prior CAR-T or bispecifics allowed if they meet the adequate organ function criteria.
✕ Known or suspected history of macrophage activation syndrome or hemophagocytic lymphohistiocytosis (HLH).